This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Oncolytic Viruses / Non-viral Gene Therapy Delivery
November 30 - December 1, 2022
Digital Conference8:00AM EST // 1:00PM GMT // 2:00PM CET
Menu
Key Sessions
Zhenghong Gao
Challenges and Opportunities for LNP Mediated Gene Delivery
Ask Bio, USA
Rui Zhang
Panel: Challenges for Non-Viral Delivery of Gene Therapies: Translating a First in Class to the Clinic
Tessera Therapeutics, USA
keyboard_arrow_right

Day 2 - Non-Viral Gene Therapy Delivery -December 1st - ET (Eastern Time, GMT-05:00)

keyboard_arrow_leftSearch & Filter
search
Day 2 - Non-Viral Gene Therapy Delivery -December 1st - ET (Eastern Time, GMT-05:00)
search
Showing 1 of 1 Streams
8:00am - 8:05am
Welcoming Remarks
  • Lottie Leinfellner - Digital Events Conference Producer, Informa Connect, UK
8:05am - 8:35am
Challenges and Opportunities for LNP Mediated Gene Delivery
  • Zhenghong Gao - Director, Non-Viral Delivery, Ask Bio, USA
8:35am - 9:05am
Gene Delivery using Red Blood Cell Extracellular Vesicles
  • Don Haut - CEO & Director, Carmine Therapeutics, USA
9:05am - 9:35am
Coffee Break & Networking
9:35am - 10:05am
The Therapeutic Potential of ORNA
  • Robert Mabry - Chief Scientific Officer, Orna Therapeutics, USA
10:05am - 10:35am
CNS Targeting Platform for the Delivery of Gene Therapies
  • Mohammad Ali Amini - President & CEO, QurCan Therapeutics Inc., Canada
10:35am - 11:05am
ACTM-838: A Novel Immunotherapy that Enriches in Solid Tumors after IV Dosing and Reverses the Immunosuppressive TME to Promote Durable Anti-Tumor Immunity
  • Akshata Udyavar - Sr. Director Immunology and Translational Sciences, Actym Therapeutics, Inc., USA
11:05am - 11:35am
Coffee Break & Networking
11:35am - 12:20pm
Panel: Challenges for Non-Viral Delivery of Gene Therapies: Translating a First in Class to the Clinic
  • Rui Zhang - Associate Director, LNP Formulation, Tessera Therapeutics, USA
  • Zhenghong Gao - Director, Non-Viral Delivery, Ask Bio, USA
  • Shashi Murthy - CTO & Co-Founder, Nanite Inc., USA
  • Florie Borel - Senior Director - Head of Delivery & Preclinical Development, Arbor Biotechnologies, USA
12:20pm - 12:50pm
Machine Learning Guided Design of Polymeric Gene Delivery Vehicles
  • Shashi Murthy - CTO & Co-Founder, Nanite Inc., USA
12:50pm - 1:20pm
Compiling a Toolbox of Genetic Editors for the Treatment of Genetic Diseases
  • Devyn M. Smith - Chief Executive Officer, Arbor Biotechnologies, USA
Day 1 - Oncolytic Viruses - November 30th
Filter
Topics
Choose Day